Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer
ConclusionIn a small number of patients, chemotherapy and pembrolizumab as first-line therapy in ERBB2-mutated NSCLC patients demonstrated activity similar to previous reports with this regimen. Future clinical trials are needed to determine the role of chemotherapy and immunotherapy for this patient population in the context of emerging targeted agents. (Source: Targeted Oncology)
Source: Targeted Oncology - March 21, 2022 Category: Cancer & Oncology Source Type: research
Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer
AbstractEstrogen receptor α (ERα) is a target for the treatment of ER-positive breast cancer patients. Paradoxically, it is also the initial site for estrogen (E2) to induce apoptosis in endocrine-resistant breast cancer. How ER α exhibits distinct functions, in different contexts, is the focus of numerous investigations. Compelling evidence demonstrated that unfolded protein response (UPR) is closely correlated with ER-positive breast cancer. Treatment with antiestrogens initially induces mild UPR through ERα with activa tion of three sensors of UPR—PRK-like endoplasmic reticulum kinase (PERK), inositol-requiring en...
Source: Targeted Oncology - March 15, 2022 Category: Cancer & Oncology Source Type: research
The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
AbstractGastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestin...
Source: Targeted Oncology - March 15, 2022 Category: Cancer & Oncology Source Type: research
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis
ConclusionsEGFR exon 20 insertion mutations are rare in NSCLC. There is a high unmet need in patients with exon 20 insertions, including effective therapies. Prospective cohort studies are needed to better clinically characterise these patients. (Source: Targeted Oncology)
Source: Targeted Oncology - February 28, 2022 Category: Cancer & Oncology Source Type: research
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
ConclusionsThe recommended phase II dose of varlitinib with paclitaxel is 300 mg twice daily intermittently dosed. This is active in HER2+ metastatic breast cancer. Subcutaneous trastuzumab can be added safely to varlitinib and paclitaxel. This combination is currently being evaluated as neoadjuvant therapy in HER2+ breast cancer (NCT02396108).Clinical Trial Registration: NCT02396108, date of registration: 25 March, 2015. (Source: Targeted Oncology)
Source: Targeted Oncology - February 23, 2022 Category: Cancer & Oncology Source Type: research
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma
AbstractDual therapy with a tyrosine kinase inhibitor (TKI) and either a programmed death protein/ligand 1 (PD-1/PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor has proven efficacy as treatment for previously-untreated advanced renal cell carcinoma (RCC). The combination of the multi-targeted TKI cabozantinib (Cabometyx®) and the anti-PD-1 monoclonal antibody nivolumab (Opdivo®) is approved as first line treatment for RCC in the EU, USA and multiple other countries. In the CheckMate 9ER trial, combination therapy with cabozantinib and nivolumab was superior to sunitinib monotherapy as first lin...
Source: Targeted Oncology - February 17, 2022 Category: Cancer & Oncology Source Type: research
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
ConclusionNotwithstanding limitations, our study found a higher proportion of psychiatric AEs with lorlatinib, but also raised the hypothesis of psychiatric reactions as a class effect of ALK TKIs. (Source: Targeted Oncology)
Source: Targeted Oncology - January 13, 2022 Category: Cancer & Oncology Source Type: research
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Na ïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
ConclusionsSafety data for afatinib when used in a “near real-world” setting in patients withEGFRm+ NSCLC was consistent with the known safety profile of afatinib. Supporting efficacy data of afatinib were provided in all patients, and in those enrolled in China. Tolerability-guided afatinib dose reduction allowed patients to remain on treatment and continue to experience clinical benefit.Trial Registration Number and Date of RegistrationNCT01953913 (1 October 2013). (Source: Targeted Oncology)
Source: Targeted Oncology - January 12, 2022 Category: Cancer & Oncology Source Type: research
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study
ConclusionsThis ROS1-positive NSCLC real-world population was older and had a higher proportion of smokers and of patients with poorer ECOG performance status than those investigated in clinical trials. Nevertheless, our findings support the clinical benefit of crizotinib in this patient population with ROS1-positive advanced NSCLC. (Source: Targeted Oncology)
Source: Targeted Oncology - December 29, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
(Source: Targeted Oncology)
Source: Targeted Oncology - December 24, 2021 Category: Cancer & Oncology Source Type: research
MYL-1402O: A Bevacizumab Biosimilar
AbstractMYL-1402O (Abevmy®, Lextemy®) is a biosimilar of the reference anti-vascular endothelial growth factor antibody bevacizumab. Abevmy® is approved for use in all indications for which reference bevacizumab is approved, including the treatment of non-small cell lung cancer (NSCLC) and other solid cancers. Lextemy® is approved for all indications as reference bevacizumab, except in recurrent ovarian cancer. MYL-1402O has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab, and the pharmacokinetic similarity of the agents has been shown in healthy male subjects. MYL-1402O demonst...
Source: Targeted Oncology - December 15, 2021 Category: Cancer & Oncology Source Type: research
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
AbstractStarting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the management of B-cell malignancies. Subsequently, more-highly selective second-generation BTK inhibitors (including acalabrutinib, zanubrutinib, tirabrutinib and orelabrutinib) have been developed, primarily with an aim to reduce off-target toxicities. More recently, third-generation agents including the non-covalent BTK inhibitors pirtobrutinib and nemtabrutinib have entered later-stage clinical development. BTK inhibitors have shown strong activity in a range of B-cel...
Source: Targeted Oncology - December 14, 2021 Category: Cancer & Oncology Source Type: research
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
ConclusionThe majority of the study population was not represented in the AURA3 trial. Survival outcomes of eligible patients are in concordance with the AURA3 trial, while OS of ineligible patients was significantly shorter compared to eligible patients. (Source: Targeted Oncology)
Source: Targeted Oncology - December 11, 2021 Category: Cancer & Oncology Source Type: research
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
ConclusionsIn patients with RCC, concomitant PPI use did not seem to affect survival outcomes on ICIs, either as combination therapy or monotherapy. (Source: Targeted Oncology)
Source: Targeted Oncology - December 11, 2021 Category: Cancer & Oncology Source Type: research
Correction to: Durvalumab: A Review in Extensive-Stage SCLC
(Source: Targeted Oncology)
Source: Targeted Oncology - December 6, 2021 Category: Cancer & Oncology Source Type: research
